论文部分内容阅读
目的分析和研究阿德福韦酯联合肝动脉灌注化疗栓塞术(TACE)介入治疗原发性肝癌临床疗效。方法 62例原发性肝癌患者,将其随机分为观察组与对照组,各31例。对照组患者采用TACE介入法治疗;观察组患者在对照组治疗基础上加用阿德福韦酯治疗,将两组患者治疗12个月后的疗效及不良反应发生率进行对比。结果两组患者治疗总有效率相比较:观察组高于对照组,差异有统计学意义(P<0.05)。两组患者不良反应发生率相比较:观察组高于对照组,差异有统计学意义(P<0.05)。结论将阿德福韦酯联合TACE介入法应用于原发性肝癌患者治疗中,其能够有效抑制肝炎病毒复制,降低肝炎病毒再激活几率,促进患者肝功能恢复,对提高治疗效果及延缓疾病发展具有重要作用。
Objective To analyze and study the clinical efficacy of adefovir dipivoxil combined with transcatheter arterial chemoembolization (TACE) in the treatment of primary liver cancer. Methods Sixty - two patients with primary liver cancer were randomly divided into observation group and control group, with 31 cases in each. The patients in the control group were treated with TACE intervention. The patients in the observation group were treated with adefovir dipivoxil on the basis of the control group, and the efficacy and the incidence of adverse reactions in both groups were compared after 12 months treatment. Results The total effective rate of the two groups was compared: the observation group was higher than the control group, the difference was statistically significant (P <0.05). Adverse reactions between the two groups were compared: the observation group was higher than the control group, the difference was statistically significant (P <0.05). Conclusion Adefovir dipivoxil combined with TACE interventional therapy in the treatment of patients with primary liver cancer, which can effectively inhibit the replication of hepatitis virus, reduce the probability of hepatitis virus reactivation, and promote the recovery of liver function, to improve the therapeutic effect and delay the development of the disease Has an important role.